Lumenis OptiLight Wins 2022 MedTech Breakthrough Award: Best New Technology Solution for Ophthalmology
Lumenis Be., a leading energy-based medical device company for aesthetic and eye care applications, today announced that OptiLight has received the highly competitive MedTech Breakthrough Award for “Best New Technology Solution for Ophthalmology.” This year, MedTech’s range of health and medical technology categories attracted more than 3,900 nominations from over 15 countries, from which MedTech selected OptiLight for this prestigious recognition. The win follows Lumenis’ MedTech awards for Best Overall Medical Device Company in 2021 and Best New Surgical Technology Solution in 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220525005607/en/
(Graphic: Business Wire)
OptiLight is a groundbreaking, light-based treatment. It is the first and only light treatment FDA approved for management of dry eye disease, a very common condition that causes dry, gritty eyes and fluctuating vision for an estimated 49 million Americans.1 Lumenis’ patented, innovative Optimal Pulse Technology (OPT™) offers targeted, uniform, precise, and controlled treatment that safely and effectively breaks the vicious cycle of inflammation associated with dry eye disease.
“Dry eye disease is highly prevalent and difficult to manage, and traditional treatments like warm compresses and artificial tears treat the symptoms but not the underlying pathology,” said James Johnson, managing director, MedTech Breakthrough. “OptiLight is leading a revolution in managing dry eye disease with ‘breakthrough’ technology that allows doctors to treat patients quickly, in-office. With broad potential for tens of millions with dry eye disease, OptiLight stands out from the crowd to become our 2022 Best New Technology Solution for Ophthalmology.”
Lumenis introduced OptiLight in May 2021 and recently launched a national media campaign featuring singer-songwriter and actress Mandy Moore (This Is Us) to increase awareness for dry eye disease and encourage people who might be suffering from this condition to seek out a physician who offers OptiLight (www.TreatMyDryEye.com).
“We’re grateful to MedTech for honoring OptiLight for its innovation and impact in eye care,” said Lumenis CEO Tzipi Ozer-Armon. “Lumenis is committed to raising the bar for patients’ health by providing cutting-edge solutions and treatment innovations. As the only light-based treatment for dry eye disease, OptiLight has the power to elevate dry eye management and improve health and quality of life for millions of people around the world.”
|
1. Dana R et al. Patient-Reported Burden of Dry Eye Disease in the United States: Results of an Online Cross-Sectional Survey. Am J Ophthalmol. 2020 Aug; 216:7-17. |
About Lumenis
Lumenis is a leading energy-based medical device company for aesthetic and ophthalmic applications in the area of minimally invasive clinical solutions. It is regarded as a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For nearly 50 years, Lumenis’ groundbreaking products have redefined medical treatments and have set numerous technological and clinical gold standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.
PB-00044810 Rev A
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220525005607/en/
Contact information
Colleen Ketchum
colleen.ketchum@precisionvh.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF to Release Fourth Quarter & Full Year 2025 Results on Feb. 11, 2026; IFF to Present at 2026 CAGNY Conference on Feb. 19, 202621.1.2026 23:15:00 EET | Press release
IFF (NYSE:IFF) today announced that it will release its fourth quarter and full year 2025 earnings results following the market close on Wednesday, Feb. 11, 2026. The management team will host a live webcast on Thursday, Feb. 12, 2026, at 9:00 a.m. ET to discuss results and outlook with the investor community. IFF also announced today that the Company’s management will speak at the Consumer Analyst Group of New York (CAGNY) conference on Thursday, Feb. 19, 2026 at 1:00 PM ET. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and en
UAE Research Program for Rain Enhancement Science Announces Awardees of 6th Cycle Grants21.1.2026 22:17:00 EET | Press release
The UAE Research Program for Rain Enhancement Science (UAEREP), managed by the National Center of Meteorology (NCM), announced the awardees of its Sixth Cycle research grants. Each recipient will receive up to US$1.5 million over three years, with a maximum annual allocation of US$550,000. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121231610/en/ UAE Research Program for Rain Enhancement Science Announces Awardees of 6th Cycle Grants (Photo: AETOSWire) The Sixth Cycle awardees are Dr. Dixon Michael, Principal Radar Meteorologist and Software Engineer at Echo Science Works, USA, for “Advancing Cloud Seeding Science with Dual-Polarization Radar Signatures and AI”; Prof. Linda Zou, Adjunct Professor at Victoria University, Australia, for “AI-assisted Development and Optimization of Glaciogenic Cloud Seeding Materials”; and Dr. Oliver Branch, Senior Scientist at the University of Hohenheim, Germany, for “Rainfall Enhanceme
Logical Intelligence Introduces First Energy-Based Reasoning AI Model, Signals Early Steps Toward AGI, Adds Yann LeCun and Patrick Hillmann to Leadership21.1.2026 20:21:00 EET | Press release
Logical Intelligence, an artificial intelligence company developing energy-based (EBM) reasoning systems, today announced that Kona 1.0, its pioneering EBM for reasoning, will enter pilot programs with select partners in the energy, advanced manufacturing, and semiconductor industries later this quarter. Logical Intelligence also released a live demonstration of Kona 1.0 on its website, beginning with head-to-head sudoku challenges against leading large language models. Additional demonstrations, including chess and Go, are planned. The company said the goal is to give researchers and the public a clear view into how energy-based reasoning differs from probabilistic systems. “Kona learns by recognizing and correcting its own mistakes, rather than guessing the most likely answer,” said Eve Bodnia, founder and CEO of Logical Intelligence. “If general intelligence means the ability to reason across domains, learn from error, and improve without being retrained for each task, then we are s
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership21.1.2026 18:35:00 EET | Press release
Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tribunal. This decision has no impact on the commercialization of Galderma’s neuromodulator portfolio. Galderma will continue to commercialize and supply Dysport®/Azzalure®, Alluzience®, and RelfydessTM in all territories where it has regulatory approval and in accordance with our existing agreements with our partner Ipsen. Progressing on our path towards becoming the undisputed dermatology powerhouse Galderma remains focused on its ambition to become the world’s undisputed dermatology powerhouse across the full spectrum of a fast-growi
ThetaRay Appoints Financial Markets Technology Leader Brad Levy as Chief Executive Officer21.1.2026 18:00:00 EET | Press release
ThetaRay, a global leader in Cognitive AI financial crime compliance, today announced the appointment of Brad Levy as Chief Executive Officer. Levy, a leading financial markets infrastructure executive and former CEO of Symphony, will lead ThetaRay’s next phase of growth as the company continues to scale its Cognitive AI platform, now emerging as the leading AI strategy and technology for transaction monitoring and transaction due diligence, across banks and fintechs worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121002476/en/ ThetaRay Appoints Brad Levy as CEO Levy brings decades of experience building and leading mission-critical financial infrastructure at scale. Most recently, he served as CEO of Symphony, the financial markets infrastructure and technology platform established by a consortium of leading global banks, including Goldman Sachs and other major financial institutions, and relied upon by hundred
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom